C. Ola Landgren, MD, PhD

C. Ola Landgren, MD, PhD

Sylvester Comprehensive Cancer Center

Professor of Medicine, Chief of Myeloma Program and Leader, Experimental Therapeutics Program

Expertise: Multiple Myeloma And Related Plasma Cell Disorders

Hematologic oncologist C. Ola Landgren, MD, PhD, is the Chief of the Myeloma Program and the inaugural leader of a new research program, Experimental Therapeutics, at Sylvester Comprehensive Cancer Center at the University of Miami Health System and the Miller School of Medicine. Dr. Landgren, previously served as Chief of Myeloma Service at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Cornell Medical College in New York City.

No Research/Citations

One thing that is sometimes a little bit overlooked is the attention to detail [that is needed] for [optimal] clinical management; [this includes] how [drugs] are delivered and all the other surrounding [factors], such as the different types of prophylactic medications, as well as fluid administration, and careful assessment of patients. Many times, people tend to forget about this. The older drugs were less effective, but they were, at the same time, potentially a little bit easier to give. The newer drugs are more effective and better, but many of them [require] more attention. You have to have good anticoagulation if you are going to use good drugs.

- https://www.onclive.com/view/landgren-spotlights-safety-considerations-for-carfilzomib-quadruplet-in-newly-diagnosed-myeloma

Available for logged-in users onlyLogin HereorRegister
close
0.07172